Ticagrelor

From Self-sufficiency
Jump to: navigation, search
Ticagrelor
File:Ticagrelor structure.svg
Systematic (IUPAC) name
(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Clinical data
Routes of
administration
oral
Identifiers
CAS Number 274693-27-5
ATC code none
PubChem CID 9871419
Synonyms AZD6140
Chemical data
Formula C23H28F2N6O4S
Molar mass 522.567 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ticagrelor (trade name Brilinta) is a platelet aggregation inhibitor produced by AstraZeneca. The PLATO clinical trial, funded by AstraZeneca, in mid-2009 found that ticagrelor had better mortality rates than clopidogrel (9.8% vs. 11.7%, p<0.001) in treating patients with acute coronary syndrome. Patients given ticagrelor were less likely to die from vascular causes, heart attack, or stroke but had slightly greater chances of major bleeding which was non-significant (11.6 vs. 11.2, p=0.4).[1]

Mechanism of action

Like prasugrel, clopidogrel and ticlopidine, ticagrelor blocks ADP receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, the blockage is reversible. Moreover, it does not need hepatic activation, which could reduce the risk of drug interactions.[2][3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
it:Ticagrelor pt:Ticagrelor
  1. Wallentin, Lars; Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Held, C; Horrow, J; Husted, S; James, S (August 30, 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". NEJM. 361 (11): 1045–57. doi:10.1056/NEJMoa0904327. PMID 19717846. 
  2. H. Spreitzer (February 4, 2008). "Neue Wirkstoffe - AZD6140". Österreichische Apothekerzeitung (in German) (3/2008): 135. 
  3. Owen, RT, Serradell, N, Bolos, J (2007). "AZD6140". Drugs of the Future. 32 (10): 845–853. doi:10.1358/dof.2007.032.10.1133832.